Rivoceranib
Gastric Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd.Small moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 63/ 100
- Competitive Position
- 89/ 100
Competitive context
280 Active assets in the Gastric Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fluorouracilum I-Mab Biopharma US Limited | Phase 4 | BB |
Xaliplatin Qilu Pharmaceutical Co., Ltd. | Phase 3 | BB |
Capecitabine I-Mab Biopharma US Limited | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Qilu Pharmaceutical Co., Ltd. | Phase 3 | BB |
Docetaxel Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Rivoceranib is also rated in:
peripheral T-cell lymphoma, not otherwise specifiedActive
BBB
Indicative · Phase 4
72 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →